These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

446 related items for PubMed ID: 19276283

  • 1. Interaction between BCL2 and interleukin-10 gene polymorphisms alter outcomes of diffuse large B-cell lymphoma following rituximab plus CHOP chemotherapy.
    Park YH, Sohn SK, Kim JG, Lee MH, Song HS, Kim MK, Jung JS, Lee JJ, Kim HJ, Kim DH.
    Clin Cancer Res; 2009 Mar 15; 15(6):2107-15. PubMed ID: 19276283
    [Abstract] [Full Text] [Related]

  • 2. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.
    Habermann TM, Weller EA, Morrison VA, Gascoyne RD, Cassileth PA, Cohn JB, Dakhil SR, Woda B, Fisher RI, Peterson BA, Horning SJ.
    J Clin Oncol; 2006 Jul 01; 24(19):3121-7. PubMed ID: 16754935
    [Abstract] [Full Text] [Related]

  • 3. Polymorphisms in cytokine genes as prognostic markers in diffuse large B cell lymphoma patients treated with (R)-CHOP.
    Liu D, Wang Y, Dong M, Guan S, Wang Y, Sun H, Wu N, Li S, Bai J, Chen F, Sun D, Jin Y.
    Ann Hematol; 2017 Feb 01; 96(2):227-235. PubMed ID: 27822610
    [Abstract] [Full Text] [Related]

  • 4. DNA repair gene XRCC1 polymorphisms and haplotypes in diffuse large B-cell lymphoma in a Korean population.
    Kim IS, Kim DC, Kim HG, Eom HS, Kong SY, Shin HJ, Hwang SH, Lee EY, Kim S, Lee GW.
    Cancer Genet Cytogenet; 2010 Jan 01; 196(1):31-7. PubMed ID: 19963133
    [Abstract] [Full Text] [Related]

  • 5. Improved therapeutic outcomes of DLBCL after introduction of rituximab in Korean patients.
    Park YH, Lee JJ, Ryu MH, Kim SY, Kim DH, Do YR, Lee KH, Oh SJ, Kim YK, Suh CW, Heo DS, Ryoo BY, Kim JK, Song HS, Lee WS, Kim HJ, Bang YJ, Yang SH, Sohn SK, Kang YK, Lymphoma Study Division of the Korean Cancer Study Group.
    Ann Hematol; 2006 Apr 01; 85(4):257-62. PubMed ID: 16416337
    [Abstract] [Full Text] [Related]

  • 6. [Comparison of rituximab plus CHOP regimen and CHOP regimen alone for treatment of newly diagnosed patients with diffuse large B-cell lymphoma].
    Wu HJ, Zhang QY, Chen DF, Guan XJ, Zhang BL, Ma J.
    Ai Zheng; 2005 Dec 01; 24(12):1498-502. PubMed ID: 16351800
    [Abstract] [Full Text] [Related]

  • 7. Mutation or polymorphism of the CD20 gene is not associated with the response to R-CHOP in diffuse large B cell lymphoma patients.
    Sar A, Perizzolo M, Stewart D, Mansoor A, Difrancesco LM, Demetrick DJ.
    Leuk Res; 2009 Jun 01; 33(6):792-7. PubMed ID: 19054557
    [Abstract] [Full Text] [Related]

  • 8. Immuno-fluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: a GELA study.
    Copie-Bergman C, Gaulard P, Leroy K, Briere J, Baia M, Jais JP, Salles GA, Berger F, Haioun C, Tilly H, Emile JF, Banham AH, Mounier N, Gisselbrecht C, Feugier P, Coiffier B, Molina TJ.
    J Clin Oncol; 2009 Nov 20; 27(33):5573-9. PubMed ID: 19786664
    [Abstract] [Full Text] [Related]

  • 9. [Comparison between R-CHOP regimen and CHOP regimen in treating naive diffuse large B-cell lymphoma in China--a multi-center randomized trail].
    Lin TY, Zhang HY, Huang Y, Guan ZZ, Shen T, Shi YK, Zhu J, Ke XY, Wang HQ, Shen ZX, Yu SY, Liu T, Shi XL.
    Ai Zheng; 2005 Dec 20; 24(12):1421-6. PubMed ID: 16351785
    [Abstract] [Full Text] [Related]

  • 10. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
    Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Fermé C, Christian B, Lepage E, Tilly H, Morschhauser F, Gaulard P, Salles G, Bosly A, Gisselbrecht C, Reyes F, Coiffier B.
    J Clin Oncol; 2005 Jun 20; 23(18):4117-26. PubMed ID: 15867204
    [Abstract] [Full Text] [Related]

  • 11. Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B-cell lymphoma.
    Hornberger JC, Best JH.
    Cancer; 2005 Apr 15; 103(8):1644-51. PubMed ID: 15756658
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia.
    Sehn LH, Donaldson J, Chhanabhai M, Fitzgerald C, Gill K, Klasa R, MacPherson N, O'Reilly S, Spinelli JJ, Sutherland J, Wilson KS, Gascoyne RD, Connors JM.
    J Clin Oncol; 2005 Aug 01; 23(22):5027-33. PubMed ID: 15955905
    [Abstract] [Full Text] [Related]

  • 15. Estimating the impact of rituximab on bcl-2-associated resistance to CHOP in elderly patients with diffuse large B-cell lymphoma.
    Mounier N, Briere J, Gisselbrecht C, Reyes F, Gaulard P, Coiffier B, Groupe d'Etude des Lymphomes de l'Adulte.
    Haematologica; 2006 May 01; 91(5):715-6. PubMed ID: 16670080
    [Abstract] [Full Text] [Related]

  • 16. Lymphotoxin alfa and receptor-interacting protein kinase 1 gene polymorphisms may correlate with prognosis in patients with diffuse large B cell lymphoma treated with R-CHOP.
    Chae YS, Kim JG, Sohn SK, Moon JH, Kim SN, Lee SJ, Park TI, Lee MH.
    Cancer Chemother Pharmacol; 2010 Feb 01; 65(3):571-7. PubMed ID: 19629486
    [Abstract] [Full Text] [Related]

  • 17. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma.
    Fu K, Weisenburger DD, Choi WW, Perry KD, Smith LM, Shi X, Hans CP, Greiner TC, Bierman PJ, Bociek RG, Armitage JO, Chan WC, Vose JM.
    J Clin Oncol; 2008 Oct 01; 26(28):4587-94. PubMed ID: 18662967
    [Abstract] [Full Text] [Related]

  • 18. Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in Chinese patients.
    Li JM, Wang L, Shen Y, Xia ZG, Chen Y, Chen QS, Chen Y, Zeng XY, You JH, Qian Y, Shen ZX.
    Ann Hematol; 2007 Sep 01; 86(9):639-45. PubMed ID: 17572895
    [Abstract] [Full Text] [Related]

  • 19. The addition of bryostatin 1 to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy improves response in a CHOP-resistant human diffuse large cell lymphoma xenograft model.
    Mohammad RM, Wall NR, Dutcher JA, Al-Katib AM.
    Clin Cancer Res; 2000 Dec 01; 6(12):4950-6. PubMed ID: 11156256
    [Abstract] [Full Text] [Related]

  • 20. Importance of maintaining the relative dose intensity of CHOP-like regimens combined with rituximab in patients with diffuse large B-cell lymphoma.
    Hirakawa T, Yamaguchi H, Yokose N, Gomi S, Inokuchi K, Dan K.
    Ann Hematol; 2010 Sep 01; 89(9):897-904. PubMed ID: 20414658
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.